We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Varian Medical Initiates Treatment Using Halcyon System
Read MoreHide Full Article
Strengthening its focus in image-guided volumetric intensity modulated radiotherapy to cancer patients, Varian Medical Systems Inc. recently announced that it has initiated treatment with its recently introduced Halcyon System. Treatment was provided at Penn Medicine to a patient suffering from head and neck cancer.
Notably, treatment using the Halcyon platform was cost effective and was of short duration. The system has been ergonomically designed to provide a user-friendly platform for clinical staff and patients.
Halcyon Unit at a Glance
Varian Medical has been taking initiatives to gain customers for its broad spectrum of products. The company unveiled the Halcyon radiotherapy treatment system at the ASTRO conference in Vienna in the third quarter.
The Halcyon radiotherapy treatment system has been designed to offer cost-effective cancer care worldwide. Halcyon received both 510(k) clearance and CE Mark from the European directive, allowing Varian Medical to start selling the system in the United States.
Per management, regulatory clearances from China and Japan should follow within the next year. During the quarter, Varian Medical booked several orders from countries like Australia, Belgium, India, Morocco, Romania, Russia, Turkey and the U.K.
Market Prospects
Strong revenue opportunity from its Oncology and Imaging Component products, growing adoption of Proton Therapy, strong overseas presence, particularly in emerging countries, and new partnership deals are positives for Varian Medical.
Data from Markets And Markets reveals that the global radiotherapy market is projected to reach a worth of $9.47 billion by 2022, at a CAGR of 6.8%. Meanwhile, other important stocks from the broader medical sector are Zimmer Biomet Holdings (ZBH - Free Report) , Abiomed Inc. and Intuitive Surgical (ISRG - Free Report) .
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Varian Medical Initiates Treatment Using Halcyon System
Strengthening its focus in image-guided volumetric intensity modulated radiotherapy to cancer patients, Varian Medical Systems Inc. recently announced that it has initiated treatment with its recently introduced Halcyon System. Treatment was provided at Penn Medicine to a patient suffering from head and neck cancer.
Notably, treatment using the Halcyon platform was cost effective and was of short duration. The system has been ergonomically designed to provide a user-friendly platform for clinical staff and patients.
Halcyon Unit at a Glance
Varian Medical has been taking initiatives to gain customers for its broad spectrum of products. The company unveiled the Halcyon radiotherapy treatment system at the ASTRO conference in Vienna in the third quarter.
The Halcyon radiotherapy treatment system has been designed to offer cost-effective cancer care worldwide. Halcyon received both 510(k) clearance and CE Mark from the European directive, allowing Varian Medical to start selling the system in the United States.
Per management, regulatory clearances from China and Japan should follow within the next year. During the quarter, Varian Medical booked several orders from countries like Australia, Belgium, India, Morocco, Romania, Russia, Turkey and the U.K.
Market Prospects
Strong revenue opportunity from its Oncology and Imaging Component products, growing adoption of Proton Therapy, strong overseas presence, particularly in emerging countries, and new partnership deals are positives for Varian Medical.
Data from Markets And Markets reveals that the global radiotherapy market is projected to reach a worth of $9.47 billion by 2022, at a CAGR of 6.8%. Meanwhile, other important stocks from the broader medical sector are Zimmer Biomet Holdings (ZBH - Free Report) , Abiomed Inc. and Intuitive Surgical (ISRG - Free Report) .
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>